- You can view the full Myriad Ratings Report.
- Use our diversified services section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Jim Cramer focuses on S&P Global, Myriad Genetics, ProLogis, Emerson Electric, Ball Corp. and more.
Jim Cramer says being a realistic investor doesn't mean being negative, especially when solid reality supports optimism.
The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.
Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.